Amneal Pharmaceuticals received FDA approval to manufacture the generic version of brand-name CARBIDOPA AND LEVODOPA formulations, providing additional competition to established Parkinson's disease treatments. This new entrant is expected to increase market competition and potentially drive down pricing for the popular oral medication.